Orbital Inflammatory Pseudotumor
Conditions
Interventions
Positive control:Treatment with oral prednisone acetate tablets
Experimental group:Oral "Qujia Hualiu Formula" combined with glucocorticoids
Sponsors
China Academy of Chinese Medical Sciences Ophthalmology Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1)No gender restriction aged 18–75 years voluntarily participating in this study. (2)Diagnosed with orbital inflammatory pseudotumor (OIPT) based on clinical manifestations medical history imaging examinations and/or pathological confirmation. (3)Signed informed consent with good compliance able to adhere to medication protocols and follow-up schedules as required by the clinical trial. (4)No significant abnormalities detected on ophthalmic specialist examinations.
Exclusion criteria
Exclusion criteria: (1)Patients with severe cardiovascular/cerebrovascular diseases or severe primary disorders of the liver kidneys or hematopoietic system. (2)Those with other orbital diseases (e.g. lymphoma orbital cellulitis rhabdomyosarcoma Graves ophthalmopathy). (3)Patients with psychiatric conditions (e.g. anxiety depression) or other mental disorders. (4)Individuals with allergic constitutions or hypersensitivity to the study drugs/components. (5)Pregnant women those planning pregnancy or lactating mothers. (6)Subjects deemed ineligible by investigators based on clinical judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intercellular adhesion molecule-1;Immunoglobulin G4(IgG4);Orbital CT;Exophthalmometry; | — |
Secondary
| Measure | Time frame |
|---|---|
| Strabismus angle (9 gaze positions);Intraocular pressure;vision;Interleukin-6(IL-6);ocular ultrasound;Tumor necrosis factor-a(TNF-a); | — |
Countries
China
Contacts
Public ContactLike Xie
China Academy of Chinese Medical Sciences Ophthalmology Hospital
Outcome results
None listed